PT - JOURNAL ARTICLE AU - Frontera, Jennifer A. AU - Yang, Dixon AU - Medicherla, Chaitanya AU - Baskharoun, Samuel AU - Bauman, Kristie AU - Bell, Lena AU - Bhagat, Dhristie AU - Bondi, Steven AU - Chervinsky, Alexander AU - Dygert, Levi AU - Fuchs, Benjamin AU - Gratch, Daniel AU - Hasanaj, Lisena AU - Horng, Jennifer AU - Huang, Joshua AU - Jauregui, Ruben AU - Ji, Yuan AU - Kahn, D. Ethan AU - Koch, Ethan AU - Lin, Jessica AU - Liu, Susan B. AU - Olivera, Anlys AU - Rosenthal, Jonathan AU - Snyder, Thomas AU - Stainman, Rebecca S. AU - Talmasov, Daniel AU - Thomas, Betsy AU - Valdes, Eduard AU - Zhou, Ting AU - Zhu, Yingrong AU - Lewis, Ariane AU - Lord, Aaron S. AU - Melmed, Kara AU - Meropol, Sharon B. AU - Thawani, Sujata AU - Troxel, Andrea B. AU - Yaghi, Shadi AU - Balcer, Laura J. AU - Wisniewski, Thomas AU - Galetta, Steven L. TI - Trajectories of Neurological Recovery 12 Months after Hospitalization for COVID-19: A Prospective Longitudinal Study AID - 10.1101/2022.02.08.22270674 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.08.22270674 4099 - http://medrxiv.org/content/early/2022/02/09/2022.02.08.22270674.short 4100 - http://medrxiv.org/content/early/2022/02/09/2022.02.08.22270674.full AB - Background/Objectives Little is known about trajectories of recovery 12-months after hospitalization for severe COVID.Methods We conducted a prospective, longitudinal cohort study of patients with and without neurological complications during index hospitalization for COVID-19 from March 10, 2020-May 20, 2020. Phone follow-up batteries were performed at 6- and 12-months post-COVID symptom onset. The primary 12-month outcome was the modified Rankin Scale (mRS) comparing patients with or without neurological complications using multivariable ordinal analysis. Secondary outcomes included: activities of daily living (Barthel Index), telephone Montreal Cognitive Assessment (t-MoCA) and Neuro-QoL batteries for anxiety, depression, fatigue and sleep. Changes in outcome scores from 6 to 12-months were compared using non-parametric paired-samples sign test.Results Twelve-month follow-up was completed in N=242 patients (median age 65, 64% male, 34% intubated during hospitalization) and N=174 completed both 6- and 12-month follow-up. At 12-months 197/227 (87%) had ≥1 abnormal metric: mRS>0 (75%), Barthel<100 (64%), t-MoCA≤18 (50%), high anxiety (7%), depression (4%), fatigue (9%) and poor sleep (10%). 12-month mRS scores did not differ significantly among those with (N=113) or without (N=129) neurological complications during hospitalization after adjusting for age, sex, race, pre-COVID mRS and intubation status (adjusted OR 1.4, 95% CI0.8-2.5), though those with neurological complications had higher fatigue scores (T-score 47 vs 44, P=0.037). Significant improvements in outcome trajectories from 6- to 12-months were observed in t-MoCA scores (56% improved, median difference 1 point, P=0.002), and Neuro-QoL anxiety scores (45% improved, P=0.003). Non-significant improvements occurred in fatigue, sleep and depression scores in 48%, 48% and 38% of patients, respectively. Barthel and mRS scores remained unchanged between 6 and 12-months in >50% of patients.Discussion At 12-months post-hospitalization for severe COVID, 87% of patients had ongoing abnormalities in functional, cognitive or Neuro-QoL metrics and abnormal cognition persisted in 50% of patients without a prior history of dementia/cognitive abnormality. Only fatigue severity differed significantly between patients with or without neurological complications during index hospitalization. However, significant improvements in cognitive (t-MoCA) and anxiety (Neuro-QoL) scores occurred in 56% and 45% of patients, respectively, between 6- to 12-months. These results may not be generalizable to those with mild/moderate COVID.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the NYU Grossman School of Medicine Institutional Review Board. All patients or their surrogates provided consent for participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors